How to Evaluate an ACT Provider in India: The Questions Every Patient Should Ask | ALIV

India's regenerative medicine market is growing rapidly — and unevenly. Between clinics with rigorous autologous protocols, experienced clinical teams, and honest outcome framing on one end, and providers offering loosely defined "cell therapy" with overstated claims and inadequate infrastructure on the other, the variation in clinical quality is significant. The patient's ability to ask the right questions is the most effective protection against the latter. This article provides a specific, practical question framework for evaluating any ACT provider — including ALIV — before committing to treatment.

The Critical Questions

1. What exactly is the cell source? The answer should be specific: bone marrow, adipose tissue, peripheral blood (for PRP). "Stem cells" is not a sufficient answer — it avoids the specificity that allows meaningful evaluation. A provider who cannot or will not specify the cell source precisely is a significant concern.

2. Is the source autologous (your own) or allogeneic (donor)? For the safety profile of autologous therapy to apply, the source must be the patient's own material from the same session. Any use of donor-derived cells represents a fundamentally different risk profile requiring different regulatory justification.

3. Is the preparation done on-site in a dedicated laboratory, on the same day as administration? Fresh, same-session preparation is the quality standard. Clinics that send material off-site for processing or that use banked or frozen preparations introduce quality and viability questions that same-day on-site processing avoids.

4. What is the regulatory basis for this specific protocol? The honest answer involves acknowledgment of the experimental or regulatory classification of the specific ACT protocol. A provider who claims full regulatory approval for all applications should be asked to specify which authority and which approval — this claim is difficult to substantiate for most ACT applications in India's current regulatory environment.

5. What are the realistic clinical outcomes for my specific condition at my specific stage? The answer should include: what proportion of patients with your condition and stage see meaningful response; what "meaningful" means in clinical terms for this condition; and what the typical response timeline is. Vague or uniformly positive answers without condition-specific nuance are a warning sign. See the ALIV approach: ACT results timeline — what to expect.

6. Who performs the harvest procedure and what is their training? Bone marrow aspiration requires specific procedural training. Adipose harvest (lipoaspiration) requires sterile technique and appropriate training. Ask specifically: who performs this procedure and what is their clinical background for this specific technique?

7. What are the documented adverse events from this clinic's ACT programme? No provider can truthfully claim zero adverse events. A provider who has performed ACT for years should have a clear and honest answer about the types of adverse events observed and their frequency and severity. Refusal to discuss adverse events is a red flag.

8. What happens if I don't respond? A good provider has a clear policy for non-response: clinical review to assess contributing factors, a clear decision framework for whether additional procedures are appropriate, and an honest conversation about when to redirect to other management. Providers who guarantee response or who have no non-response pathway have not thought through the clinical reality of their programme.

Is it appropriate to get a second opinion before ACT?

Yes — and ALIV explicitly encourages it. The decision to proceed with ACT for a chronic condition is significant, and any patient who wants a second clinical opinion from another provider before committing is making an informed and reasonable choice. ALIV's clinical team provides complete documentation of the proposed protocol, the clinical rationale, and the realistic outcome framing for any patient seeking a second opinion.

How does ALIV answer these questions?

Autologous, same-day, on-site fresh preparation; bone marrow or adipose tissue by condition; ICU-trained nursing and trained physician for harvest; proprietary experimental protocol with honest outcome framing; documented adverse event monitoring; and clear non-response policy. ALIV has been building this clinical standard since 2015 — and welcomes the scrutiny that informed patients bring.